Lucid Diagnostics Inc (NAS:LUCD)
$ 0.788 0.021 (2.74%) Market Cap: 45.52 Mil Enterprise Value: 99.85 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 44/100

Lucid Diagnostics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 12, 2022 / 05:30PM GMT
Release Date Price: $2.54 (-9.29%)
Mike Matson
Needham & Company, LLC - Analyst

Thanks for joining us again at the 21st Annual Needham Healthcare Conference. I'm Mike Matson, and I lead the medtech equity research team here at Needham & Company. I am pleased to introduce Lucid Diagnostics. We have Lucid's CEO, Lishan Aklog; CFO, Dennis McGrath; and VP of Investor Relations, Adrian Miller.

Instead of a standard presentation, we are going to do a Q&A session. If you have any questions you would like me to ask, you can submit them electronically through the Needham conference website or feel free to email them to me at [email protected]. And I'll do my best to fit them in.

So as I noted, we are going to go straight into Q&A here.

Questions & Answers

Mike Matson
Needham & Company, LLC - Analyst

So we'll start with EsoGuard. You've developed this innovative test and sample collection system for esophageal precancer, called EsoGuard and EsoCheck. It was wondering if you could give us an overview of esophageal cancer, why it's so deadly, and what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot